Welcome to our dedicated page for Protagenic Therapeutics news (Ticker: PTIX), a resource for investors and traders seeking the latest updates and insights on Protagenic Therapeutics stock.
Protagenic Therapeutics, Inc. (NASDAQ: PTIX) is a biopharmaceutical company developing neuro-active peptide and related therapeutics for stress-related and central nervous system (CNS) disorders. The PTIX news feed on Stock Titan highlights company announcements that explain how its clinical programs, business transactions, and listing status are evolving over time.
Investors following PTIX news can read detailed updates on the company’s lead peptide candidate, PT00114, including milestones in single ascending dose and multiple-dose Phase 1 studies in healthy volunteers. Recent press releases describe safety, tolerability, and pharmacokinetic findings for PT00114, as well as the company’s plans to use Phase 1 data to support advancement into Phase 2 studies in stress-related and mood disorders such as depression, anxiety, and PTSD.
News coverage also includes pipeline and corporate developments, such as the announced business combination with Phytanix Bio Inc. to form a combined entity called Phytanix, Inc. Company statements outline how this transaction adds preclinical CNS assets, including a potassium channel modulator, cannabinoid-based compounds with composition-of-matter IP, and modified stilbenoid candidates with anticonvulsant activity in preclinical models.
In addition, PTIX news items feature capital markets and regulatory updates, including private placements, warrant exercises, a 1-for-14 reverse stock split intended to address Nasdaq minimum bid price requirements, and Nasdaq notices related to continued listing standards and periodic filing timelines. Legal filings connected to the Phytanix share exchange agreement and other governance matters are also reported through current reports and press releases. By reviewing this news stream, readers can see how Protagenic describes the progress of its CNS-focused pipeline, its financing activities, and its efforts to manage exchange listing and regulatory obligations.
Protagenic Therapeutics (OTCQB:PTIX) completed a separation from Phytanix on March 17, 2026, returning and cancelling 117,690 merger shares and reducing shares outstanding to 1,810,208 as of March 5, 2026.
The transaction removed >$6.3 million of liabilities (total liabilities cut to ~ $0.5 million), eliminated >$1 million of annualized costs, resolved merger-related litigation, and refocused capital and management on lead asset PT00114 with positive Phase 1 multiple-dose safety data and Phase 2 enrollment planned for 2026.
Protagenic Therapeutics (OTCQB: PTIX) announced an upgrade from OTC Pink to OTCQB and commenced trading on OTCQB under the symbol PTIX on March 10, 2026. The move is intended to improve market visibility, trading liquidity and access to real-time quotes.
The company said it completed a Phase 1 multiple-dose safety study showing a clean safety and tolerability profile and remains on track to begin Phase 2 enrollment in 2026 for lead candidate PT00114 targeting treatment-resistant depression and anxiety.
Protagenic Therapeutics (NASDAQ:PTIX) reported positive topline safety results from its Phase 1 multiple-dose study of PT00114 in healthy volunteers on December 9, 2025. All planned cohorts completed dosing and PT00114 was reported as well tolerated across all dose ranges. No serious adverse events were observed; reported adverse events were consistent with a peptide injectable, including expected injection-site reactions. Several participants reported an improved sense of well-being (anecdotal). The company is finalizing full Phase 1 analyses and expects to initiate a Phase 2 study in early 2026 to evaluate PT00114 in chronic stress-related psychiatric disorders.
Protagenic Therapeutics (NASDAQ:PTIX) announced completion of enrollment and dosing in its Multiple Ascending Dose (MAD) Phase 1 study of lead peptide PT00114 in healthy volunteers on November 13, 2025. The trial evaluated safety and tolerability after multiple doses. The company said it will deliver a full summation of safety analysis by the end of the month and expects to release top-line MAD results by November 30, 2025. Protagenic noted it previously completed a single ascending dose study in early 2025 and described PT00114 as a first-in-class candidate targeting resilience to chronic stress and related neurological effects.
Protagenic Therapeutics (Nasdaq:PTIX), a biopharmaceutical company, announced a delay in filing its Q2 2025 Form 10-Q due to ongoing merger-related financial consolidation work. The company received a Nasdaq notice on August 20, 2025 regarding non-compliance with Listing Rule 5250(c)(1).
The delay is attributed to the need to complete merger-related financial consolidation, including purchase accounting adjustments and pro forma financial information. While PTIX's securities continue trading on Nasdaq Capital Market, the company plans to regain compliance promptly upon filing and will submit a compliance plan if necessary.
Protagenic Therapeutics (NASDAQ:PTIX) has announced significant progress in the clinical development of PT00114, its novel neuro-active peptide therapy. The company has completed first dose injection for all subjects in the multiple-dose portion of its Phase 1 trial, with full dosing completion expected by August end 2025.
PT00114 is pioneering as the first investigational therapy based on Teneurin C-terminus Associated Peptide (TCAP), a natural brain hormone that regulates stress and emotional balance. The drug targets the amygdala and hippocampus, offering a differentiated approach to treating anxiety, depression, addiction, and PTSD.
Following successful completion of a single ascending dose trial demonstrating favorable safety, the company anticipates topline safety data by September 2025 and plans to advance to Phase 2 efficacy studies in Q1 2026.
Protagenic Therapeutics (Nasdaq: PTIX) has secured a new Japanese patent (JP 7714571B) for its modified stilbenoid program drug candidates, valid until March 31, 2041. The patent covers compounds, formulations, and medical applications specifically targeting epilepsy and seizure treatments.
This development follows the previous grant of the same patent in the UK (Patent GB2609814). The company plans to pursue patent protection in additional territories to strengthen its development pipeline and intellectual property portfolio.
PROG Holdings (NYSE:PRG) has reported that warrant exchanges and exercises over the past four trading days have generated $3.1 million in cash proceeds. The company plans to use these funds for working capital needs and to advance its development of peptide-based drug candidates targeting stress-related and central nervous system disorders.
The financing coincides with Protagenic's recently announced business combination with Phytanix Bio Inc. (May 19, 2025), which has consolidated six complementary drug development programs focusing on stress disorders, epilepsy, obesity, and other indications under one organization.